Turn Therapeutics (TTRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.57, -8.80% vs the prior close of $11.59.
- Volume 105.61K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TTRX slides 8.8% to $10.57, a 1-month low. Closed at $10.57, -8.80% vs the prior close of $11.59. Day range $10.39–$11.49, opened at $11.49.
TTRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TTRX slides 8.8% to $10.57, a 1-month low
- Closed at $10.57, -8.80% vs the prior close of $11.59. Day range $10.39–$11.49, opened at $11.49.
- Volume was 105.61K shares, 0.9x its 50-day average of 114.78K.
- Price is -9.0% vs its 50-day average ($11.61) and +57.7% vs its 200-day average ($6.70).
- 52-week range $2.57–$16.45; today's close sits at 58% of that range, 35.7% below the 52-week high.
Oct 15, 2026 — TTRX jumps 4.3% to $11.59
- Closed at $11.59, +4.32% vs the prior close of $11.11. Day range $10.85–$11.89, opened at $10.85.
- Volume was 80.30K shares, 0.7x its 50-day average of 113.84K.
- Price is -0.0% vs its 50-day average ($11.59) and +73.8% vs its 200-day average ($6.67).
- 52-week range $2.57–$16.45; today's close sits at 65% of that range, 29.5% below the 52-week high.
Oct 14, 2026 — TTRX jumps 4.8% to $11.11
- Closed at $11.11, +4.81% vs the prior close of $10.60. Day range $10.42–$11.44, opened at $10.42.
- Volume was 53.40K shares, 0.5x its 50-day average of 113.67K — lighter than usual.
- Price is -3.8% vs its 50-day average ($11.55) and +67.6% vs its 200-day average ($6.63).
- 52-week range $2.57–$16.45; today's close sits at 62% of that range, 32.5% below the 52-week high.
Oct 13, 2026 — TTRX slides 4.6% to $10.60, a 1-month low
- Closed at $10.60, -4.59% vs the prior close of $11.11. Day range $10.26–$11.40, opened at $11.12.
- Volume was 117.40K shares, 1.1x its 50-day average of 111.57K.
- Price is -8.0% vs its 50-day average ($11.52) and +61.0% vs its 200-day average ($6.59).
- 52-week range $2.57–$16.45; today's close sits at 58% of that range, 35.6% below the 52-week high.
Oct 12, 2026 — TTRX slides 7.4% to $11.11, a 1-month low
- Closed at $11.11, -7.42% vs the prior close of $12.00. Day range $11.03–$11.98, opened at $11.72.
- Volume was 45.90K shares, 0.4x its 50-day average of 111.58K — lighter than usual.
- Price is -3.2% vs its 50-day average ($11.48) and +69.7% vs its 200-day average ($6.55).
- 52-week range $2.57–$16.45; today's close sits at 62% of that range, 32.5% below the 52-week high.
Oct 9, 2026 — TTRX jumps 5.4% to $12.00
- Closed at $12.00, +5.36% vs the prior close of $11.39. Day range $11.30–$12.00, opened at $11.34.
- Volume was 109.80K shares, 1.0x its 50-day average of 111.12K.
- Price is +5.0% vs its 50-day average ($11.43) and +84.4% vs its 200-day average ($6.51).
- 52-week range $2.57–$26.50; today's close sits at 39% of that range, 54.7% below the 52-week high.
Oct 8, 2026 — TTRX slides 5.9% to $11.39, a 1-month low
- Closed at $11.39, -5.87% vs the prior close of $12.10. Day range $11.24–$12.00, opened at $11.94.
- Volume was 110.10K shares, 1.0x its 50-day average of 110.37K.
- Price is +0.3% vs its 50-day average ($11.35) and +76.3% vs its 200-day average ($6.46).
- 52-week range $2.57–$26.50; today's close sits at 37% of that range, 57.0% below the 52-week high.
Oct 7, 2026 — TTRX jumps 4.0% to $12.10
- Closed at $12.10, +3.95% vs the prior close of $11.64. Day range $11.31–$13.05, opened at $11.58.
- Volume was 175.70K shares, 1.6x its 50-day average of 107.78K.
- Price is +7.3% vs its 50-day average ($11.27) and +88.5% vs its 200-day average ($6.42).
- 52-week range $2.57–$26.50; today's close sits at 40% of that range, 54.3% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — TTRX slides 5.8% to $11.64
- Closed at $11.64, -5.83% vs the prior close of $12.36. Day range $11.57–$12.42, opened at $12.35.
- Volume was 74.80K shares, 0.7x its 50-day average of 107.78K.
- Price is +4.1% vs its 50-day average ($11.18) and +82.6% vs its 200-day average ($6.37).
- 52-week range $2.57–$26.50; today's close sits at 38% of that range, 56.1% below the 52-week high.
Oct 5, 2026 — TTRX slides 7.3% to $12.36
- Closed at $12.36, -7.28% vs the prior close of $13.33. Day range $12.00–$13.18, opened at $13.18.
- Volume was 111.30K shares, 1.0x its 50-day average of 107.55K.
- Price is +11.3% vs its 50-day average ($11.11) and +95.2% vs its 200-day average ($6.33).
- 52-week range $2.57–$26.50; today's close sits at 41% of that range, 53.4% below the 52-week high.
Oct 2, 2026 — TTRX ends flat (+0.2%) to $13.33
- Closed at $13.33, +0.15% vs the prior close of $13.31. Day range $12.17–$13.48, opened at $13.35.
- Volume was 136.30K shares, 1.3x its 50-day average of 106.16K.
- Price is +20.8% vs its 50-day average ($11.03) and +112.1% vs its 200-day average ($6.28).
- 52-week range $2.57–$26.50; today's close sits at 45% of that range, 49.7% below the 52-week high.
TTRX latest news & SEC filings
Every SEC filing by or about TTRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$5.85M (prior year -$1.24M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.20 (prior year -$0.05) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade TTRX
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 31, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.14% (largest 11.6%). That is a volatile stock.
- Liquidity: about 110.97K shares (≈$1.17M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $10.57 vs a range of $2.57–$16.45 (58% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Zuraiz Chaudhary bought 2,500 shares on Dec 12, 2025.
- Latest filings: 8-K Oct 7, 2026; 8-K Sep 10, 2026; 8-K Sep 9, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TTRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.49 | 11.49 | 10.39 | 10.57 | 105.61K |
| Oct 15, 2026 | 10.85 | 11.89 | 10.85 | 11.59 | 80.30K |
| Oct 14, 2026 | 10.42 | 11.44 | 10.42 | 11.11 | 53.40K |
| Oct 13, 2026 | 11.12 | 11.40 | 10.26 | 10.60 | 117.40K |
| Oct 12, 2026 | 11.72 | 11.98 | 11.03 | 11.11 | 45.90K |
| Oct 9, 2026 | 11.34 | 12.00 | 11.30 | 12.00 | 109.80K |
| Oct 8, 2026 | 11.94 | 12.00 | 11.24 | 11.39 | 110.10K |
| Oct 7, 2026 | 11.58 | 13.05 | 11.31 | 12.10 | 175.70K |
| Oct 6, 2026 | 12.35 | 12.42 | 11.57 | 11.64 | 74.80K |
| Oct 5, 2026 | 13.18 | 13.18 | 12.00 | 12.36 | 111.30K |
| Oct 2, 2026 | 13.35 | 13.48 | 12.17 | 13.33 | 136.30K |
| Oct 1, 2026 | 14.25 | 14.25 | 13.02 | 13.31 | 122.00K |
| Sep 30, 2026 | 13.41 | 14.63 | 13.02 | 14.39 | 88.70K |
| Sep 29, 2026 | 13.04 | 13.89 | 12.85 | 13.41 | 79.50K |
| Sep 28, 2026 | 12.29 | 13.12 | 12.28 | 13.04 | 76.70K |
| Sep 25, 2026 | 13.24 | 13.68 | 12.30 | 12.49 | 90.00K |
| Sep 24, 2026 | 13.50 | 13.88 | 12.06 | 13.26 | 244.90K |
| Sep 23, 2026 | 15.30 | 15.65 | 13.50 | 13.51 | 101.60K |
| Sep 22, 2026 | 15.31 | 15.44 | 14.53 | 15.29 | 122.50K |
| Sep 21, 2026 | 15.05 | 15.56 | 13.59 | 15.34 | 172.90K |
About Turn Therapeutics
Turn Therapeutics (TTRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WESTLAKE VILLAGE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2023016.
TTRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bradley Evan Burnam | Chief Executive Officer | Jun 1, 2026 |
| Martin William Dewhurst | Director | Jun 8, 2026 |
| Arthur F Golden | Director | Jun 8, 2026 |
| Andrew Gengos | Director | Jun 8, 2026 |
| Neilesh Shailesh Ghodadra | Chief Medical Officer | Oct 10, 2025 |
| Kent Edward Kester | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Bradley Evan Burnam | Chief Executive Officer | Jun 1, 2026 |
| Zuraiz Chaudhary | See Remarks | Apr 3, 2026 |
| Neilesh Shailesh Ghodadra | Chief Medical Officer | Oct 10, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 12, 2025 | Zuraiz Chaudhary | Buy | 2,500 | $3.50 |
| Dec 12, 2025 | Zuraiz Chaudhary | Buy | 2,500 | $3.50 |
| Dec 12, 2025 | Zuraiz Chaudhary | Buy | 2,500 | $3.50 |
| Dec 12, 2025 | Zuraiz Chaudhary | Buy | 2,500 | $3.50 |
| Nov 24, 2025 | Arthur F Golden | Buy | 9,868 | $3.44 |
| Nov 24, 2025 | Arthur F Golden | Buy | 9,868 | $3.44 |
| Nov 24, 2025 | Arthur F Golden | Buy | 9,868 | $3.44 |
| Nov 24, 2025 | Arthur F Golden | Buy | 9,868 | $3.44 |
| Nov 21, 2025 | Arthur F Golden | Buy | 20,532 | $2.87 |
| Nov 21, 2025 | Arthur F Golden | Buy | 20,532 | $2.87 |
| Nov 21, 2025 | Arthur F Golden | Buy | 20,532 | $2.87 |
| Nov 21, 2025 | Arthur F Golden | Buy | 20,532 | $2.87 |
| Nov 21, 2025 | Zuraiz Chaudhary | Buy | 1,000 | $3.29 |
| Nov 21, 2025 | Zuraiz Chaudhary | Buy | 1,000 | $3.29 |
| Nov 21, 2025 | Zuraiz Chaudhary | Buy | 1,000 | $3.29 |
TTRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-3.19M | -0.12 | $-2.56M |
| Dec 31, 2024 | — | $-1.77M | -0.07 | $-1.36M |
Latest balance sheet: total assets $16.96M, total liabilities $16.27M, cash $9.95M (as of Jun 30, 2026).
TTRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $10.54 |
| May 11, 2026 | 8-K Item 2.02 (results) | $3.88 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $3.20 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $4.09 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TTRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.